How OX40-Targeted Therapies Might Reshape Biologic Strategy in AD
Dermatology Times
MAY 5, 2025
Christopher Bunick, MD, PhD, discusses the evolving role of OX40-targeted biologics in atopic dermatitis treatment ahead of the upcoming RAD conference.
Let's personalize your content